Unknown PHASE2 INTERVENTIONAL 1-arm NCT03923179

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

The Efficacy and Safety of Pyrotinib Combined With Etoposide in HER2-positive Advanced Breast Cancer

Sponsor: Chinese Academy of Medical Sciences

Updated 7 times since 2019 Last updated: Apr 18, 2019 Started: Apr 19, 2019 Primary completion: Apr 1, 2021 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Breast Cancer, this trial is ongoing. The trial is conducted by Chinese Academy of Medical Sciences and has accumulated 7 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2023 — Jul 2024 [monthly]

Unknown Status PHASE2
Dec 2022 — Oct 2023 [monthly]

Unknown Status PHASE2
Jan 2022 — Dec 2022 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Jan 2021 — Jan 2022 [monthly]

Recruiting PHASE2
May 2019 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Academy of Medical Sciences

Data source: ChineseAMS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China